natgillin/translations-raw huggingface dataset:
The following additional adverse reaction has been observed in a study of patients with dementia associated with Parkinson’s disease treated with rivastigmine transdermal patches: agitation (common).
V študiji pri bolnikih, ki so imeli demenco v povezavi s Parkinsonovo boleznijo in so bili zdravljeni s transdermalnimi obliži z rivastigminom, so opazili naslednji neželeni učinek: agitiranost (pogosti).
The following additional adverse reactions have been observed with rivastigmine transdermal patches: delirium, pyrexia, decreased appetite, urinary incontinence (common), psychomotor hyperactivity (uncommon), erythema, urticaria, vesicles, allergic dermatitis (not known).
Pri uporabi transdermalnih obližev rivastigmina so dodatno opažali še naslednje neželene učinke: delirij, zvišano telesno temperaturo, zmanjšan apetit, urinska inkontinenca (pogosti), psihomotorična hiperaktivnost (občasni), eritem, urtukarija, vezikli, alergijski dermatitis (neznana).
The following additional adverse reactions have been reported during post–marketing experience; they are derived from spontaneous reports and therefore, the frequency of these adverse reactions is not known:
Po pridobitvi dovoljenja za promet so poročali o naslednjih dodatnih neželenih učinkih, ki izhajajo iz spontanih poročil, zato je pogostnost teh neželenih učinkov neznana:
The following additional adverse reactions suspected to be immune-related have been reported in < 2% of patients treated with ipilimumab 3 mg/kg monotherapy: uveitis, eosinophilia, lipase elevation, and glomerulonephritis.
O naslednjih dodatnih neželenih učinkih, domnevno povezanih z imunskim dogajanjem, so poročali pri manj kot 2 % bolnikov, ki so ipilimumab prejemali v odmerku 3 mg/kg kot monoterapijo: uveitis, eozinofilija, zvišanje vrednosti lipaze in glomerulonefritis.
The following additional adverse reactions suspected to be immune-related have been reported in patients treated with ipilimumab 3 mg/kg monotherapy in MDX010-20: uveitis, eosinophilia, lipase elevation, and glomerulonephritis.
V študiji MDX010-20 so pri bolnikih, ki so se zdravili z ipilimumabom v odmerku 3 mg/kg kot monoterapija, poročali še o naslednjih, domnevno imunsko pogojenih neželenih učinkih: uveitisu, eozinofiliji, zvišanju vrednosti lipaze in glomerulonefritisu.
The following additional adverse reactions were reported from post-marketing surveillance with egg-based seasonal trivalent vaccines:
Iz spremljanja v obdobju trženja so poročali o naslednjih dodatnih neželenih učinkih s sezonskimi trivalentnimi cepivi na osnovi jajc:
The following additional clinically significant, immune-related adverse reactions have been reported in patients receiving pembrolizumab: uveitis, arthritis, myositis, pancreatitis, severe skin reactions, Guillain-Barré syndrome, myasthenic syndrome, haemolytic anaemia and partial seizures arising in a patient with inflammatory foci in brain parenchyma (see section 4.8).
Pri bolnikih, ki so prejemali pembrolizumab, so poročali o naslednjih klinično pomembnih imunsko pogojenih neželenih učinkih: uveitisu, artritisu, miozitisu, pankreatitisu, hudih kožnih reakcijah, Guillain-Barréjevem sindromu, miasteničnem sindromu, hemolitični anemiji in delnih epileptičnih napadih, ki so se pojavili pri bolnikih z vnetnimi žarišči v parenhimu možganov (glejte poglavje 4.8).
The following additional risk minimisation measures are necessary for the safe and effective use of the product:
Za varno in učinkovito uporabo zdravila so nujni naslednji dodatni ukrepi za zmanjševanje tveganj:
The following additional side effects have been observed with Simponi:
Pri uporabi zdravila Simponi so opažali naslednje dodatne neželene učinke:
The following additional undesirable effects have been reported following the widespread use of HEXAVAC.
O spodaj navedenih neželenih učinkih so poročali po začetku splošne uporabe HEXAVAC-a,
The following adverse effects were reported very rarely: allergic reaction, chills, fatigue, hypotonic- hyporesponsive episode, malaise, oedema, pallor, swelling or oedema of the entire limb(s), transient local lymph node swelling, convulsions (febrile and non febrile), encephalitis, encephalopathy with acute brain oedema, eyes rolling, Guillain Barré Syndrome, hypotonia, neuritis, abdominal pain, meteorism, nausea, petechiae, purpura, purpura thrombocytopenic, thrombocytopenia, agitation, sleep disorder, dyspnoea or Stridor inspiratory, angioedema, erythema, pruritus, rash, urticaria and flushing.
Zelo redko pa poročajo o naslednjih neželenih učnikih: alergične reakcije, mrzlica, utrujenost, hipotonična-hipoodzivna epizoda, splošna slabost, edem bledica, otekanje ali edem celotnega uda(ov), prehodno otekanje lokalnih limfnih vozljev, krči (vročinski in nevročinski), encefalitis, encefalopatija za akutnim edemom v možganih, vrtenje oči, sindrom Guillain Barré hipotonija, nevritis, bolečine v trebuhu meteorizem, slabost, petehije, purpura, trombocitopenična purpura, trombocitopenija, razburjenje, motnje spanja, oteženo dihanje ali škripavo vdihovanje, angioedem, rdeč kožni madeži, srbečica, izpuščaj, urtikarija in rdenje.
The following adverse event listings are based on reports from clinical trials (Table 1, adverse events and laboratory abnormalities) and from post-marketing surveillance (Table 2, frequencies - where known - based on pooled clinical trials (very common 1/10, common 1/100 to <1/10, uncommon
Spodnja seznama neželenih učinkov temeljita na poročilih iz kliničnih raziskav (preglednica 1, neželeni učinki in nenormalni rezultati laboratorijskih preiskav) in iz nadzora v obdobju trženja zdravila Extavia (preglednica 2, pogostnosti, ki – kjer je to znano - temeljijo na združenih podatkih iz kliničnih študij (zelo pogosti 1/10, pogosti 1/100 do <1/10, občasni 1/1.000 do <1/100, redki
The following adverse events have been reported with some statins:
Pri nekaterih statinih so poročali o naslednjih neželenih učinkih:
The following adverse events were reported more commonly in paediatric Crohn’s disease patients in the REACH study (see section 5.1) than in adult Crohn’s disease patients: anaemia (10.7%), blood in stool (9.7%), leucopenia (8.7%), flushing (8.7%), viral infection (7.8%), neutropenia (6.8%), bone fracture (6.8%), bacterial infection (5.8%), and respiratory tract allergic reaction (5.8%).
Naslednje neželene učinke so v preskušanju REACH prijavljali pogosteje pri pediatričnih bolnikih s Crohnovo boleznijo (glejte poglavje 5.1) kot pri odraslih bolnikih s Crohnovo boleznijo: anemija (10,7 %), kri v blatu (9,7 %), levkopenija (8,7 %), pordelost (8,7 %), virusne okužbe (7,8 %), nevtropenija (6,8 %), zlomi kosti (6,8 %), bakterijske okužbe (5,8 %), alergijske reakcije dihal (5,8 %).
The following adverse events were uncommon (i.e. in 0.1%-1 % of dogs):
Sledeči neželeni učinki so bili redki (pri 0,1 – 1% psov):
The following adverse events which occurred during clinical studies were considered to be related to the use of EVICEL:
Za naslednje neželene učinke, ki so se pojavili med kliničnimi študijami, je bilo ocenjeno, da bi utegnili biti vzročno povezani z uporabo zdravila EVICEL:
The following adverse reactions (Grade ≥ 3) were observed at a higher incidence in the Bortezomib Accord containing treatment regimen as compared with a historical control study in which the backbone regimen was given alone: in Block 1 peripheral sensory neuropathy (3% versus 0%); ileus (2.1% versus 0%); hypoxia (8% versus 2%).
V shemi zdravljenja z dodanim zdravilom Bortezomib Accord so se naslednji neželeni učinki (stopnje ≥ 3) pojavili pogosteje kot v predhodni kontrolni študiji, kjer so bolniki prejemali samo osnovno shemo zdravljenja: v 1. sklopu periferna senzorična nevropatija (3 % proti 0 %), ileus (2,1 % proti 0 %), hipoksija (8 % proti 2 %).
The following adverse reactions (Grade ≥ 3) were observed at a higher incidence in the bortezomib containing treatment regimen as compared with a historical control study in which the backbone regimen was given alone: in Block 1 peripheral sensory neuropathy (3% versus 0%); ileus (2.1% versus 0%); hypoxia (8% versus 2%).
V shemi zdravljenja z bortezomibom so se naslednji neželeni učinki (stopnje≥ 3) pojavili pogosteje kot v predhodni kontrolni študiji, kjer so bolniki prejemali samo osnovno shemo zdravljenja: v 1. sklopu periferna senzorična nevropatija (3% proti 0%), ileus (2,1% proti 0%), hipoksija (8% proti 2%).
The following adverse reactions (Grade ≥ 3) were observed at a higher incidence in the VELCADE containing treatment regimen as compared with a historical control study in which the backbone regimen was given alone: in Block 1 peripheral sensory neuropathy (3% versus 0%); ileus (2.1% versus 0%); hypoxia (8% versus 2%).
V shemi zdravljenja z dodanim zdravilom VELCADE so se naslednji neželeni učinki (stopnje ≥ 3) pojavili pogosteje kot v predhodni kontrolni študiji, kjer so bolniki prejemali samo osnovno shemo zdravljenja: v 1. sklopu periferna senzorična nevropatija (3% proti 0%), ileus (2,1% proti 0%), hipoksija (8% proti 2%).
The following adverse reactions are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from available data).
Naslednji neželeni učinki so razvrščeni po naslednjem dogovoru: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do < 1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000) ali neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
The following adverse reactions are expected under the use of MIRAPEXIN: abnormal dreams, amnesia, behavioural symptoms of impulse control disorders and compulsions such as binge eating, compulsive shopping, hypersexuality and pathological gambling; cardiac failure, confusion, constipation, delirium, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hiccups, hyperkinesia, hyperphagia, hypotension, inappropriate antidiuretic hormone secretion, insomnia, libido disorders, mania, nausea, paranoia, peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity; restlessness, somnolence, sudden onset of sleep, syncope, visual impairment including diplopia, vision blurred and visual acuity reduced, vomiting, weight decrease including decreased appetite, weight increase.
Pričakovani neželeni učinki med zdravljenjem z zdravilom MIRAPEXIN so: nenormalne sanje, amnezija, vedenjski simptomi motenj nadzora impulzov in kompulzije, kot so prenajedanje in kompulzivno nakupovanje, hiperseksualnost in patološko hazardiranje; srčno popuščanje stanje zmedenosti, zaprtost, delirij, omotica, blodnje, diskinezije, dispneja, utrujenost, halucinacije, glavobol, kolcanje, hiperkinezija, hiperfagija, hipotenzija, neustrezno izločanje antidiuretičnega hormona, nespečnost, motnje libida, manija, slabost, paranoja, periferni edem, pljučnica, pruritus, izpuščaj in druge oblike preobčutljivosti; nemir, zaspanost, nenaden nepremagljiv spanec, sinkopa, okvara vida, tudi diplopija, meglen vid in zmanjšane ostrine vida, bruhanje, zmanjšanje telesne mase, tudi zmanjšan tek, povečanje telesne mase.
The following adverse reactions are expected under the use of MIRAPEXIN: abnormal dreams, amnesia, behavioural symptoms of impulse control disorders and compulsions such as binge eating, compulsive shopping, hypersexuality and pathological gambling; cardiac failure, confusion, constipation, delirium, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hiccups, hyperkinesia, hyperphagia, hypotension, inappropriate antidiuretic hormone secretion, insomnia, libido disorders, mania, nausea, paranoia, peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity; restlessness, somnolence, sudden onset of sleep, syncope, visual impairment including diplopia, vision blurred and visual acuity reduced, vomiting, weight decrease including decreased appetite, weight increase.
Pričakovani neželeni učinki med zdravljenjem z zdravilom MIRAPEXIN so: nenormalne sanje, amnezija, vedenjski simptomi motenj nadzora impulzov in kompulzije, kot so prenajedanje in kompulzivno nakupovanje, hiperseksualnost in patološko hazardiranje; srčno popuščanje, stanje zmedenosti, zaprtost, delirij, omotica, blodnje, diskinezije, dispneja, utrujenost, halucinacije, glavobol, kolcanje, hiperkinezija, hiperfagija, hipotenzija, neustrezno izločanje antidiuretičnega hormona, nespečnost, motnje libida, manija, slabost, paranoja, periferni edem, pljučnica, pruritus, izpuščaj in druge oblike preobčutljivosti; nemir, zaspanost, nenaden nepremagljiv spanec, sinkopa, okvara vida, tudi diplopija, meglen vid in zmanjšane ostrine vida, bruhanje, zmanjšanje telesne mase, tudi zmanjšan tek, povečanje telesne mase.
The following adverse reactions are expected under the use of Oprymea: abnormal dreams, amnesia, behavioural symptoms of impulse control disorders and compulsions such as binge eating, compulsive shopping, hypersexuality and pathological gambling; cardiac failure, confusion, constipation, delirium, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hiccups, hyperkinesia, hyperphagia, hypotension, inappropriate antidiuretic hormone secretion, insomnia, libido disorders, mania, nausea, paranoia, peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity; restlessness, somnolence, sudden onset of sleep, syncope, visual impairment including diplopia, vision blurred and visual acuity reduced, vomiting, weight decrease including decreased appetite, weight increase.
Pričakovani neželeni učinki med zdravljenjem z zdravilom Oprymea so: nenormalne sanje, amnezija, vedenjski simptomi motenj nadzora impulzov in kompulzije, kot so prenajedanje in kompulzivno nakupovanje, hiperseksualnost in patološko hazardiranje; srčno popuščanje stanje zmedenosti, delirij, zaprtost, omotica, blodnje, diskinezije, dispneja, utrujenost, halucinacije, glavobol, kolcanje, hiperkinezija, hiperfagija, hipotenzija, neustrezno izločanje antidiuretičnega hormona, nespečnost, motnje libida, manija, slabost, paranoja, periferni edem, pljučnica, pruritus, izpuščaj in druge oblike preobčutljivosti; nemir, zaspanost, nenaden nepremagljiv spanec, sinkopa, okvara vida, tudi diplopija, meglen vid in zmanjšane ostrine vida, bruhanje, zmanjšanje telesne mase, tudi zmanjšan tek, povečanje telesne mase.
The following adverse reactions are expected under the use of Oprymea: abnormal dreams, amnesia, behavioural symptoms of impulse control disorders and compulsions such as binge eating, compulsive shopping, hypersexuality and pathological gambling; cardiac failure, confusion, constipation, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hiccups, hyperkinesia, hyperphagia, hypotension, inappropriate antidiuretic hormone secretion, insomnia, libido disorders, nausea, paranoia, peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity; restlessness, somnolence, sudden onset of sleep, syncope, visual impairment including diplopia, vision blurred and visual acuity reduced, vomiting, weight decrease including decreased appetite, weight increase.
Pričakovani neželeni učinki med zdravljenjem z zdravilom Oprymea so: nenormalne sanje, amnezija, vedenjski simptomi motenj nadzora impulzov in kompulzije, kot so prenajedanje in kompulzivno nakupovanje, hiperseksualnost in patološko hazardiranje; srčno popuščanje stanje zmedenosti, zaprtost, omotica, blodnje, diskinezije, dispneja, utrujenost, halucinacije, glavobol, kolcanje, hiperkinezija, hiperfagija, hipotenzija, neustrezno izločanje antidiuretičnega hormona, nespečnost, motnje libida, slabost, paranoja, periferni edem, pljučnica, pruritus, izpuščaj in druge oblike preobčutljivosti; nemir, zaspanost, nenaden nepremagljiv spanec, sinkopa, okvara vida, tudi diplopija, meglen vid in zmanjšane ostrine vida, bruhanje, zmanjšanje telesne mase, tudi zmanjšan tek, povečanje telesne mase.
The following adverse reactions are expected under the use of Pramipexole Teva: abnormal dreams, amnesia, behavioural symptoms of impulse control disorders and compulsions such as binge eating, compulsive shopping, hypersexuality and pathological gambling; cardiac failure, confusion, constipation, delirium, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hiccups, hyperkinesia, hyperphagia, hypotension, inappropriate antidiuretic hormone secretion, insomnia, libido disorders, mania, nausea, paranoia, peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity; restlessness, somnolence, sudden onset of sleep, syncope, visual impairment including diplopia, vision blurred and visual acuity reduced, vomiting, weight decrease including decreased appetite, weight increase.
Med jemanjem zdravila Pramipeksol Teva lahko pričakujemo naslednje neželene učinke: nenavadne sanje, amnezija, vedenjski simptomi motenj nadzora impulzov in kompulzije, kot so prenajedanje in kompulzivno nakupovanje, hiperseksualnost in patološko hazardiranje, srčno popuščanje, zmedenost, zaprtje, delirij, blodnje, vrtoglavico, diskinezijo, dispnejo, utrujenost, halucinacije, glavobol, kolcanje, hiperkinezije, hiperfagija, hipotenzijo, neustrezno izločanje antidiuretičnega hormona, povečano nespečnost, motnje libida, manija, slabost, paranoja, periferne otekline, pljučnica, pruritus, izpuščaj in druge oblike preobčutljivosti; nemir, zaspanost, nenaden nepremagljiv spanec, sinkopa, okvare vida, tudi diplopija, meglen vida in zmanjšanje ostrine vida, bruhanje, zmanjšanje telesne mase, tudi zmanjšan tek, povečanje telesne mase.
The following adverse reactions are expected under the use of pramipexole: abnormal dreams, amnesia, behavioural symptoms of impulse control disorders and compulsions such as binge eating, compulsive shopping, hypersexuality and pathological gambling; cardiac failure, confusion, constipation, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hiccups, hyperkinesia, hyperphagia, hypotension, inappropriate antidiuretic hormone secretion, insomnia, libido disorders, nausea, paranoia, peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity; restlessness, somnolence, sudden onset of sleep, syncope, visual impairment including diplopia, vision blurred and visual acuity reduced, vomiting, weight decrease including decreased appetite, weight increase.
Pričakovani neželeni učinki med zdravljenjem s pramipeksolom so nenavadne sanje, amnezija, vedenjski simptomi motenj nadzora impulzov in kompulzije, kot so prenajedanje in kompulzivno nakupovanje, hiperseksualnost in patološko hazardiranje, srčno popuščanje, zmedenost, zaprtost, blodnje, omotica, diskinezija, dispneja, utrujenost, halucinacije, glavobol, kolcanje, hiperkinezija, hiperfagija, hipotenzija, neustrezno izločanje antidiuretičnega hormona,, nespečnost, motnje libida, slabost, periferni edem, pljučnica, paranoja, patološko hazardiranje, hiperseksualnost in druge oblike nenormalnega vedenja, zaspanost, nenaden nepremagljiv spanec, sinkopa, okvara vida, tudi diplopija, meglen vid in zmanjšanje ostrine vida, bruhanje, zmanjšanje telesne mase, tudi zmanjšan tek, povečanje telesne mase.
The following adverse reactions are expected under the use of SIFROL: abnormal dreams, amnesia, behavioural symptoms of impulse control disorders and compulsions such as binge eating, compulsive shopping, hypersexuality and pathological gambling; cardiac failure, confusion, constipation, delirium, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hiccups, hyperkinesia, hyperphagia, hypotension, inappropriate antidiuretic hormone secretion, insomnia, libido disorders, mania, nausea, paranoia, peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity; restlessness, somnolence, sudden onset of sleep, syncope, visual impairment including diplopia, vision blurred and visual acuity reduced, vomiting, weight decrease including decreased appetite, weight increase.
Pričakovani neželeni učinki med zdravljenjem z zdravilom SIFROL so: nenormalne sanje, amnezija, vedenjski simptomi motenj nadzora impulzov in kompulzije, kot so prenajedanje in kompulzivno nakupovanje, hiperseksualnost in patološko hazardiranje; srčno popuščanje stanje zmedenosti, zaprtost, delirij, omotica, blodnje, diskinezije, dispneja, utrujenost, halucinacije, glavobol, kolcanje, hiperkinezija, hiperfagija, hipotenzija, neustrezno izločanje antidiuretičnega hormona, nespečnost, motnje libida, manija, slabost, paranoja, periferni edem, pljučnica, pruritus, izpuščaj in druge oblike preobčutljivosti; nemir, zaspanost, nenaden nepremagljiv spanec, sinkopa, okvara vida, tudi diplopija, meglen vid in zmanjšane ostrine vida, bruhanje, zmanjšanje telesne mase, tudi zmanjšan tek, povečanje telesne mase.
The following adverse reactions are expected under the use of SIFROL: abnormal dreams, amnesia, behavioural symptoms of impulse control disorders and compulsions such as binge eating, compulsive shopping, hypersexuality and pathological gambling; cardiac failure, confusion, constipation, delirium, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hiccups, hyperkinesia, hyperphagia, hypotension, inappropriate antidiuretic hormone secretion, insomnia, libido disorders, mania, nausea, paranoia, peripheral oedema, pneumonia, pruritus, rash and other hypersensitivity; restlessness, somnolence, sudden onset of sleep, syncope, visual impairment including diplopia, vision blurred and visual acuity reduced, vomiting, weight decrease including decreased appetite, weight increase.
Pričakovani neželeni učinki med zdravljenjem z zdravilom SIFROL so: nenormalne sanje, amnezija, vedenjski simptomi motenj nadzora impulzov in kompulzije, kot so prenajedanje in kompulzivno nakupovanje, hiperseksualnost in patološko hazardiranje; srčno popuščanje stanje zmedenosti, zaprtost, delirij, omotica, blodnje, diskinezije, dispneja, utrujenost, halucinacije, glavobol, kolcanje, hiperkinezija, hiperfagija, hipotenzija, neustrezno izločanje antidiuretičnega hormona, nespečnost, motnje libida,manija, slabost, paranoja, periferni edem, pljučnica, pruritus, izpuščaj in druge oblike preobčutljivosti; nemir, zaspanost, nenaden nepremagljiv spanec, sinkopa, okvara vida, tudi diplopija, meglen vid in zmanjšane ostrine vida, bruhanje, zmanjšanje telesne mase, tudi zmanjšan tek, povečanje telesne mase.
The following adverse reactions are frequently observed with docetaxel: Immune system disorders
Pri docetakselu so pogosto opažali naslednje neželene učinke: Bolezni imunskega sistema
The following adverse reactions are frequently observed with docetaxel: Immune system disorders
Z docetakselom so pogosto opažali naslednje neželene učinke: Bolezni imunskega sistema
The following adverse reactions are frequently observed with docetaxel: Immune system disorders
Z docetakselom so pogosto opažali naslednje neželene učinke: Bolezni imunskega sistema:
The following adverse reactions emerging from clinical trials in LHON patients or reported post- marketing in other indications are tabulated below.
V spodnji preglednici so povzeti neželeni učinki, ki so se pojavili med kliničnimi preskušanji pri bolnikih z LKON ali v obdobju trženja pri drugih indikacijah.
The following adverse reactions have also been reported when nevirapine has been used in combination with other anti-retroviral agents: pancreatitis, peripheral neuropathy and thrombocytopaenia.
Med dajanjem nevirapina v kombinaciji z drugimi protiretrovirusnimi zdravili so poročali o naslednjihneželenih učinkih: pankreatitisu, periferni nevropatiji in trombocitopeniji.